Will Sorafenib be included in medical insurance in 2025? Any news?

Sorafenib/Nexavar (Sorafenib), as a targeted drug widely used to treat a variety of tumors, has been widely used in the domestic market, especially in the treatment of hepatocellular carcinoma, renal cell carcinoma and thyroid cancer, and has shown good efficacy. Since its approval in 2007, sorafenib has become one of the core drugs for the clinical treatment of these tumors due to its multi-target mechanism of action. In China, sorafenib has been included in medical insurance, and according to the adjustments to the national medical insurance policy in recent years, it is expected that its medical insurance reimbursement will be further optimized in 2025, especially in terms of medical insurance payment ratio and patient cost burden.

As my country attaches increasing importance to cancer treatment, the country has gradually increased its support for anti-tumor drugs, especially drugs with significant curative effects like sorafenib. In 2025, with the gradual adjustment of the national medical insurance catalog, more anti-cancer drugs may be included in the scope of medical insurance reimbursement, and the medical insurance payment ratio may further increase, which will help reduce the financial burden of patients and improve the accessibility of treatment for patients. As an important drug for the treatment of liver cancer and kidney cancer, sorafenib has a great chance of entering medical insurance in the future, especially its application prospects in the field of domestic tumor treatment are becoming more and more extensive.

In addition, with the continuous optimization of national policies, especially in the medical insurance reimbursement policy for anti-tumor drugs, the future development of sorafenib in the domestic market will become increasingly secure. Taking into account the growing demand for global anti-cancer drugs, sorafenib's market share is also expected to further expand with policy support. Therefore, patients can look forward to further expansion of sorafenib’s medical insurance coverage in the near future, and more patients will be able to benefit from it.

Reference materials:https://www.nexavar.com/